针对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌分离株检测的德拉氟沙星的体外活性
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
作者信息
Flamm Robert K, Rhomberg Paul R, Huband Michael D, Farrell David J
机构信息
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.
Abstract
Delafloxacin, an investigational anionic fluoroquinolone, is active against a broad range of Gram-positive and Gram-negative bacteria. In this study, 200 Streptococcus pneumoniae (plus 30 levofloxacin-resistant isolates), 200 Haemophilus influenzae, and 100 Moraxella catarrhalis isolates selected primarily from the United States (2014) were tested against delafloxacin and comparator agents. Delafloxacin was the most potent agent tested. MIC50 and MIC90 values against all S. pneumoniae isolates were 0.008 and 0.015 μg/ml. Delafloxacin susceptibility was not affected by β-lactamase status against H. influenzae and M. catarrhalis.
摘要
德拉氟沙星是一种处于研究阶段的阴离子氟喹诺酮类药物，对多种革兰氏阳性菌和革兰氏阴性菌均有活性。在本研究中，主要从美国（2014年）选取了200株肺炎链球菌（外加30株耐左氧氟沙星菌株）、200株流感嗜血杆菌和100株卡他莫拉菌，对其进行了德拉氟沙星和对照药物的测试。德拉氟沙星是所测试药物中效力最强的。针对所有肺炎链球菌分离株的MIC50和MIC90值分别为0.008和0.015μg/ml。针对流感嗜血杆菌和卡他莫拉菌，德拉氟沙星的敏感性不受β-内酰胺酶状态的影响。
相似文献
1
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.
2
Multicenter surveillance of antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan during the 1998-1999 respiratory season.
Antimicrob Agents Chemother. 2000 May;44(5):1342-5. doi: 10.1128/AAC.44.5.1342-1345.2000.
3
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.
4
In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Antimicrob Agents Chemother. 2000 Feb;44(2):447-9. doi: 10.1128/AAC.44.2.447-449.2000.
5
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
Int J Antimicrob Agents. 2001 Jun;17(6):457-64. doi: 10.1016/s0924-8579(01)00334-x.
6
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Antimicrob Agents Chemother. 2003 Jun;47(6):1790-7. doi: 10.1128/AAC.47.6.1790-1797.2003.
7
Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.
Antimicrob Agents Chemother. 1999 Nov;43(11):2612-23. doi: 10.1128/AAC.43.11.2612.
8
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Clin Infect Dis. 2012 Sep;55 Suppl 3:S187-93. doi: 10.1093/cid/cis561.
9
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
J Clin Microbiol. 1999 Jun;37(6):1999-2002. doi: 10.1128/JCM.37.6.1999-2002.1999.
10
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Antimicrob Agents Chemother. 2003 Jun;47(6):1875-81. doi: 10.1128/AAC.47.6.1875-1881.2003.
引用本文的文献
1
Structural basis of topoisomerase targeting by delafloxacin.
Nat Commun. 2025 Jul 1;16(1):5829. doi: 10.1038/s41467-025-60688-3.
2
Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae.
Rev Esp Quimioter. 2024 Apr;37(2):158-162. doi: 10.37201/req/107.2023. Epub 2024 Jan 16.
3
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1304. doi: 10.3390/ph16091304.
4
Updated Review on Clinically-Relevant Properties of Delafloxacin.
Antibiotics (Basel). 2023 Jul 28;12(8):1241. doi: 10.3390/antibiotics12081241.
5
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.
Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022.
6
Potential new fluoroquinolone treatments for suspected bacterial keratitis.
BMJ Open Ophthalmol. 2022 Jul;7(1). doi: 10.1136/bmjophth-2022-001002.
7
Clinical Utility of Lefamulin: If Not Now, When?
Curr Infect Dis Rep. 2020;22(9):25. doi: 10.1007/s11908-020-00732-z. Epub 2020 Jul 9.
8
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Drugs. 2020 Aug;80(12):1247-1258. doi: 10.1007/s40265-020-01358-0.
9
Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01131-19. Print 2019 Oct.
10
Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials.
Infect Drug Resist. 2019 May 27;12:1415-1423. doi: 10.2147/IDR.S202160. eCollection 2019.
本文引用的文献
1
Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Feb;55(2):649-58. doi: 10.1128/AAC.01201-10. Epub 2010 Dec 6.
2
New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria.
Clin Infect Dis. 2007 Jan 15;44(2):280-6. doi: 10.1086/510431. Epub 2006 Dec 7.
3
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Antimicrob Agents Chemother. 2004 Jul;48(7):2771-7. doi: 10.1128/AAC.48.7.2771-2777.2004.
4
The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
J Antimicrob Chemother. 2004 Jul;54(1):281-2. doi: 10.1093/jac/dkh304. Epub 2004 Jun 9.
5
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
J Antimicrob Chemother. 2004 May;53(5):783-92. doi: 10.1093/jac/dkh180. Epub 2004 Mar 31.
6
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
7
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. doi: 10.1128/AAC.47.10.3260-3269.2003.
8
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11. doi: 10.1128/AAC.47.9.3008-3011.2003.
9
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Antimicrob Agents Chemother. 2003 Jun;47(6):1875-81. doi: 10.1128/AAC.47.6.1875-1881.2003.
10
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Antimicrob Agents Chemother. 2003 Jun;47(6):1867-74. doi: 10.1128/AAC.47.6.1867-1874.2003.
Zotero 插件